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The RPE65 gene encodes the isomerase of the retinoid cycle, the
enzymatic pathway that underlies mammalian vision. Mutations in
RPE65 disrupt the retinoid cycle and cause a congenital human
blindness known as Leber congenital amaurosis (LCA). We used
adeno-associated virus-2-based RPE65 gene replacement therapy to
treat three young adults with RPE65-LCA and measured their vision
before and up to 90 days after the intervention. All three patients
showed a statistically significant increase in visual sensitivity at 30
days after treatment localized to retinal areas that had received the
vector. There were no changes in the effect between 30 and 90 days.
Both cone- and rod-photoreceptor-based vision could be demon-
strated in treated areas. For cones, there were increases of up to 1.7
log units (i.e., 50 fold); and for rods, there were gains of up to 4.8 log
units (i.e., 63,000 fold). To assess what fraction of full vision potential
was restored by gene therapy, we related the degree of light sensi-
tivity to the level of remaining photoreceptors within the treatment
area. We found that the intervention could overcome nearly all of the
loss of light sensitivity resulting from the biochemical blockade.
However, this reconstituted retinoid cycle was not completely nor-
mal. Resensitization kinetics of the newly treated rods were remark-
ably slow and required 8 h or more for the attainment of full
sensitivity, compared with <1 h in normal eyes. Cone-sensitivity
recovery time was rapid. These results demonstrate dramatic, albeit
imperfect, recovery of rod- and cone-photoreceptor-based vision
after RPE65 gene therapy.
dark adaptation  photoreceptor  retinal degeneration  retinoid cycle
The enzymatic pathway in the human eye that regenerateslight-altered vitamin A molecules is known as the retinoid
cycle of vision. Molecular defects in retinoid cycle genes can lead
to inherited retinal diseases in man (1). The severity of visual
disturbance in these diseases is thought to be related to how the
mutation alters the biochemical activity and whether there is
redundancy at the multiple biochemical steps of the cycle. A
severe form of incurable childhood blindness, Leber congenital
amaurosis (LCA), is caused by mutations in RPE65 (retinal
pigment epithelium-specific protein, 65 kDa), the gene in the
retinal pigment epithelium (RPE) that encodes the isomerase.
This is the only known enzyme that catalyzes isomerization of
all-trans-retinyl esters to 11-cis-vitamin A. In RPE65 deficiency,
photoreceptor cells do not regenerate their visual pigment and
vision is not sustained. Retinal anatomy also degenerates, but
not entirely (2, 3).
RPE65-deficient animals have been characterized, and proof-
of-principle studies using recombinant adeno-associated virus
(AAV) vector delivery of RPE65 to RPE cells have described
restoration of vision (2, 4–14). These studies provided the
impetus for human safety studies of RPE65 gene replacement
(trials NCT00481546, NCT00643747, NCT00516477, and
NCT00422721, www.clinicaltrials.gov). Early reports from hu-
man retinal gene replacement trials suggest there are no short-
term safety concerns and that modest increases in visual function
can be found in some of the subjects (15–17).
Key scientific questions were not answered in these recent human
studies. It remains unclear whether rod or cone vision, or both, were
restored. It is also unknown whether any vision improvement was
complete and fully explained by the level of potentially rescuable
photoreceptors remaining in the treatment area. To determine if
the genetically flawed retinoid cycle could be restored, we used
AAV-basedRPE65 gene replacement in three young adult subjects
with severe visual loss caused by recessive RPE65 mutations. Rod
and cone visual parameters were studied before and after inter-
vention. Rod photoreceptor-based vision was present in all patients
after treatment. Unexpectedly, rod kinetics of dark adaptation, a
surrogate for retinoid cycle activity (18), were remarkably slow.
Increased cone photoreceptor-based vision was demonstrated in
two of the patients. Comparison of photoreceptor nuclear layer
structure and co-localized visual function indicated that the inter-
vention had ameliorated the severe retinoid cycle blockade com-
ponent of this complex disease and converted it to a simpler
photoreceptor degeneration.
Results
Human Gene Therapy Surmounts Biochemical Blockade in RPE65-LCA.
The retinoid cycle enzymatic pathway allows continuous vision by
regeneration of 11-cis- from all-trans-retinal (Fig. 1 A and B).
AAV2-based RPE65 gene replacement was delivered by injection
(5.96  1010 vg in 150 l) between the RPE cell layer and the
photoreceptor layer (Fig. 1C) into one eye (i.e., study eye) of three
RPE65-LCA subjects. Subjects’ ages were 24 years (patient 1), 23
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years (patient 2) and 21 years (patient 3) and all had severe vision
disturbances from childhood. The disease-causing RPE65 muta-
tions (patient 1, E417Q/E417Q; patient 2, R91W/R44Q; patient 3,
Y368H/Y368H) were reported in vitro to have less than 3%
isomerization activity compared with WT (19, 20). The photore-
ceptor cell layer thickness in all three patients was reduced but
sufficiently detectable to warrant treatment. Treatment involved
the inferior retina in patient 1, superior retina in patient 2, and the
far temporal retina in patient 3 (Fig. 1D). The biological activity of
the human vector unused in the treatment syringe was proven with
an in vivo bioassay in Rpe65-deficient rd12 mice [supporting
information (SI) Fig. S1A].
Patient 1 showed increased vertical extent of daylight visual field
in the study eye versus the control eye when measured at 30 days
after treatment (Fig. 2A). Therewas increased light sensitivity in the
treated inferior retina compared with pretreatment results (Fig. 2
A and B). The effect in patient 1 was present at 1 month as well as
2 and 3 months after treatment; there was no major change in the
lateral extent or magnitude of the visual gain during this interval
(Fig. 2 A and B). Retinal loci corresponding to a contiguous region
extending more than 4mm showed statistically significant increases
of sensitivity in the study eye; there were no significant changes in
the control eye (Fig. 2B).
Patient 2 described a localized increase in brightness as early as
7 to 10 days after treatment. This self-reported increase in visual
sensitivity posttreatment is earlier than times previously reported in
most animal studies (2, 8, 9, 12, 14). Thus, biological activity was
studied in rd12mice at 10 days after treatment with the clinical trial
vector and compared with control injections. Even at this early
Fig. 1. Schematic of the retina, retinoid cycle, and localized delivery of gene
therapy in three patients with inherited blindness. (A) Light enters the eye and
is absorbed by visual pigments (rhodopsin) in photoreceptors of the retina
(red), the complex brain-like neural layer. (B) The retinoid cycle and its
isomerase, RPE65, converts all-trans- to 11-cis-retinal to regenerate the visual
pigment. (C) Series of retinal cross-sections from patient 2 rendered in three
dimensions and overlaid onto the ocular fundus view illustrate the superior
retinal site of subretinal vector injection. Fovea and optic nerve head locations
are shown. (D) Photoreceptor cell layer (i.e., ONL) thickness topography
(pseudocolor scale) in a normal subject and pretreatment in study eyes of
patients 1, 2, and 3 (P1, P2, and P3). Site of injection (syringe tip) and the
estimate of the bleb formed by the injection (dashed circle) are shown. Data
in C and D are shown in equivalent left retina representation for clarity.
Fig. 2. Biological activity resulting from localized gene therapy in three
patients with inherited blindness. (A) Clinical kinetic visual field maps (repre-
sented as left retina for clarity and comparability) in control (blue) and study
eyes at 1 month after treatment (red) are shown. Light sensitivity measures in
study eyes along vertical (patients 1 and 2) and horizontal (patient 3) merid-
ians at 1, 2, and 3 months after treatment compared with before treatment are
also shown. The increased superior (patient 1), inferior (patient 2), and tem-
poral (patient 3) retinal extent of vision boundary on visual field maps of study
eyes corresponds to the region of vector injection. These regions show in-
creases in light sensitivity after treatment compared with before treatment.
(B) Retinal loci demonstrating significant change (stars) in light sensitivity at
1, 2, and 3 months after treatment compared with before treatment. All
significant changes were increases in sensitivity (ranging from 1 to 3 log units)
and correspond to regions of study eyes that received gene therapy; control
eyes of the three patients did not show significant changes. Test-retest vari-
ability estimated from five additional patients with RPE65-LCA along the
vertical meridian was smaller than the magnitude of sensitivity changes
observed in study eyes. Biological activity in the study eye of patient 3 is
assumed to cover a large contiguous region even though significance could be
mathematically determined only at a subset of far temporal loci where
pretreatment sensitivities were available. The baseline for each patient cor-
responds to the mean of two visits within 20 months of treatment. F, fovea.








posttreatment time, there was a robust electroretinographic re-
sponse to the vector and no such response from control injections
with vehicle (Fig. S1B). Daylight visual fields in patient 2 at 30 days
after treatment showed increased vertical extent in the study eye
compared with the control eye (Fig. 2A). Visual thresholds mea-
sured in the dark revealed greater light sensitivity in the superior
retina, a region included in the injection (Fig. 1D). No change in the
lateral extent or magnitude of the visual gain was detectable
between days 30 and 90 posttreatment (Fig. 2A andB). Statistically
significant increases covered a contiguous retinal region of more
than 6mm; therewere no significant changes in the control eye (Fig.
2B). Test–retest variability in other RPE65-LCA patients was
smaller than the extent of the increases observed in the treated eyes
of patients 1 and 2 (Fig. 2B).
Patient 3 also reported increased light sensitivity in the study
eye at 7 to 10 days after treatment. Daylight visual fields were
increased in horizontal extent compared with the control eye at
30 days after treatment (Fig. 2A). Visual testing in the dark at
loci representing the far temporal retina revealed a wide region
with increased sensitivity compared with pretreatment results.
The effect was statistically significant, persistent upon re-tests at
60 and 90 days after treatment, and covered a retinal region
greater than 10 mm in extent. There were no significant changes
in sensitivity in the control eye. Pupillary reactions in the dark
(21, 22) also indicated increased light sensitivity in the study eyes
of patients 2 and 3; this method showed no detectable change in
sensitivity in the study eye of patient 1 or the control eyes of all
three patients (Fig. S2).
ExtendedDark Adaptation Reveals a GreaterMagnitude of Visual Gain
After Treatment.Normal human vision becomes more sensitive to
light after an instantaneous decrease in ambient illumination—
the process is known as dark adaptation. Normally, full dark
adaptation can require up to 1 hour for rod photoreceptor-based
night vision (18, 23–27); further changes in light sensitivity after
1 hour are insignificant in normal eyes. Accordingly, initial
testing in all patients was performed after a standard dark
adaptation period of 1 to 2 h. Clues to the inadequacy of this
period were suggested from reports by the subjects of noticeably
increased brightness in their treated eye when they awoke from
sleep in their darkened rooms. To understand the pathophysi-
ology underlying these reports, testing was repeated after allow-
ing adaptation of eyes to darkness for extended periods (3–8 h).
Under these conditions, all three patients showed dramatic
further gains in the magnitude of their visual sensitivity. Mean
gains were 0.9, 1.3, and 0.7 log units within the treated regions
of patients 1, 2, and 3, respectively (Fig. 3A); untreated retinal
regions showed no significant sensitivity changes with extended
adaptation (not shown). These results suggested that the kinetics
of the reconstituted retinoid cycle in the study eyes may be
abnormally slow. Further, spatially non-uniform improvements
observed across the treated retina in all patients indicated large
differences in the kinetics of dark adaptation may be present.
Adaptation Kinetics for Treated Cones Are Rapid, but Treated Rod
Recovery Takes Many Hours. To define the kinetics of dark adap-
tation in treated retinas and to differentiate rod from cone
kinetics, chromatic sensitivities were measured before and after
a desensitizing light flash (Fig. 3B). In patient 2, two retinal loci
within the treated superior retinal region were studied, whereas
in patient 3 a single locus was tested in the far temporal retina;
patient 1 did not have sufficient visual function to permit reliable
testing. Within 1 minute after the flash, visual function was
detectable, and it was mediated by the cone system (Fig. 3B).
Cone-mediated function remained on a plateau (25), essentially
unchanged for more than 120 min, compared with the same
period lasting only 7 to 9 min in normal eyes. Emergence of rod
function defined the end of the cone-plateau phase at 2 h for
patient 2 at 3.6 mm superior retina and patient 3 at 17 mm
temporal retina; patient 2 at 7.2 mm superior retina remained on
the cone plateau for 4 h (Fig. 3B). Rod photoreceptor-
Fig. 3. Rod- and cone-photoreceptor-mediated visual function across the
retinal region of study eyes showing biological activity. (A) The magnitude of the
biological activity can be improved by allowing for a period of extended dark
adaptation (Ext DA) before testing. Changes in the shapes of the light sensitivity
profiles inpatient1andpatient2betweenstandarddarkadaptation(StdDA)and
extended dark adaptation conditions suggest local differences in adaptation
rate. (B) Dark adaptation kinetics measured with chromatic stimuli after a 7 log
scot-td.s yellow adapting flash (presented at time 0) in patient 2 (at 3.6 and 7.2
mm inferior loci) and patient 3 (at 17 mm temporal locus). Also shown are
detailed results from one normal (N) subject at 3.6 mm inferior (Left) and mean
results from normal subjects at each location (gray lines). Cone adaptation
kinetics (red symbols) are fast and do not show a difference from healthy cones.
Rod adaptation kinetics (blue symbols) are extremely slow compared with
healthy rods, and in patient 2 there is evidence for a large intraretinal difference
in recovery rate. Additionally, absolute thresholds of both rod and cone systems
are abnormally elevated. Note, the vertical threshold scale is inverted compared
to the sensitivity scale inA to be consistent with traditional presentations of such
data sets. (C) Maximal improvement in rod-mediated function (blue) across the
region of treated retina ranged from 2.3 log in patient 1, 4.8 log in patient 2, and
4.5 log in patient 3; cone vision improvements (red) range from 1.7 log in patient
2 to 1.2 log in patient 3. Note that pretreatment estimates for rod- or cone-
mediated vision (dashed lines) are best-case extrapolations from achromatic
sensitivity measures. Only in patient 2 were pretreatment chromatic sensitivities
measurable at 1–3 mm superior retina, and these measures were consistent with
cone mediation. For patient 1, after treatment, specialized testing with a 4°
diameter stimuluscenteredat4.8mminferior retinasuggestedrodmediationfor
the blue stimulus. Pretreatment (Pre) results are from18 to3 months before
treatment; posttreatment (Post) results are from 1–3 months after treatment.
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mediated recovery in both patients progressed slowly, lasting at
least 8 h. The shape of the rod recovery function could be
described with two log-linear segments in patient 2 at the 3.6 mm
superior locus with slopes of 0.6 h1 and 0.18 h1 (corre-
sponding to time constants of 43 and 145 min); the exact shapes
of the other two recovery functions were less discernible but the
major log-linear segments had slopes of 0.6 h1. In normal
eyes, rod recovery following a similar flash shows two log-linear
segments with slopes of 0.25 min1 and 0.04 min1 (corre-
sponding to time constants of 1.7 and 11 min).
Rod- and Cone-Based Vision Increases After Gene Therapy. Cone
function was evaluated across the treated retinal regions of
patients 2 and 3 during the extended cone-plateau phase of dark
adaptation with chromatic stimuli (Fig. 3C). At retinal regions
with peak biological activity, cone-mediated sensitivities in-
creased by at least 1.7 log units in patient 2 and 1.2 log units in
patient 3 compared with the most conservative (i.e., best-case)
estimates of pretreatment cone vision (Fig. 3C, red dashed lines).
In both patients, cone function posttreatment remained1.5 log
units less sensitive than normal. Cone vision in patient 1 was not
detectable with the brightest available long-wavelength stimulus
(implying a loss of greater than 2.6–3.4 log units, depending on
retinal location) before or after treatment.
Under standard dark adaptation conditions, rod-mediated func-
tion was discernible after treatment in patients 2 and 3 (Fig. 3C)
demonstrating 2.3 and 3.1 log units of increased sensitivity on
average compared with conservative estimates of pretreatment rod
vision (Fig. 3C). With an extended period of dark adaptation,
rod-mediated function showed further gains of 1.7 log units in
patient 2 and 1.0 log unit in patient 3 and became detectable in
patient 1 (Fig. 3C). The rod function gain observed in patient 2 was
not uniform (Fig. 3C), consistent with the large intraretinal differ-
ence in rate of dark adaptation in this subject (Fig. 3B). Posttreat-
ment rod function reached within 1.5 log units of normal vision in
patient 2 and within 2.2 log units in patient 3 but remained4 log
units less sensitive than normal in patient 1.
Gene Replacement Converts RPE65-LCA from a Complex to a Simpler
Disease. RPE65-LCA is a complex retinal disease in which visual
loss is caused by a combination of a biochemical blockade of the
retinoid cycle and degeneration of retinal photoreceptors. In hu-
man patients, as well as in canine andmurinemodels, disease stages
with partial degeneration of photoreceptors show a dissociation of
retinal function from retinal structure whereby the loss of visual
function can be orders ofmagnitude greater than expected from the
partial loss of retinal photoreceptors alone (2). Gene replacement
therapy would be hypothesized to ameliorate the functional block-
ade but not replace cells lost as a result of degeneration. To test this
hypothesis, we determined the relationship between retinal struc-
ture and function in patients 1 and 2 over a 2-mm expanse of
retina corresponding to each individual’s region of peak biological
activity (Fig. 4); data on retinal structure could not be obtained
within the far temporal locus of patient 3. Photoreceptor layer
(outer nuclear layer, ONL) thickness was 29% of mean normal
thickness for patient 1 and 43% for patient 2. Patients with retinitis
pigmentosa with degenerative photoreceptor loss but without
RPE65 mutations who have ONL thickness values similar to those
of patients 1 and 2 showed sensitivity losses ranging from 0.5 to 2.5
log units, consistent (to within measurement variability) with the
predictions (0.7–1.1 log units) of a theoretical model (Fig. 4B).
Pretreatment conservative estimates of the loss of rod function for
patients 1 and 2 were 7.2 log and 6.4 log, respectively. After
treatment, patient 1 showed a 2.3 log unit increase in rod sensitivity,
which approached, but did not reach, the predictions of the simple
photoreceptor degeneration (Fig. 4B). Patient 2, conversely,
showed a posttreatment visual gain of 4.8 log units (i.e., 63,000 fold)
and the result became no different from that expected of simpler
diseases with only a degenerative component contributing to the
vision loss (Fig. 4B). Thus, gene therapy shows the potential to
provide dramatic, albeit imperfect, restoration of the retinoid cycle
disease component in RPE65-LCA.
Discussion
Clinical trials of uniocular subretinal gene therapy in patients
with RPE65-LCA were initiated after proof-of-concept studies
using subretinal delivery of vector gene showed restored vision
in Rpe65-deficient dogs (4, 5, 8, 11, 12) and mice (2, 6, 7, 9, 10,
13, 29, 30). Short-term safety results from three human clinical
trials were recently reported: there were no serious adverse
events in all subjects, and vision improved in some subjects
(15–17). In the current study, we explored in detail the basis of
increased vision resulting from the intervention.
Rod photoreceptor-based night vision increased in sensitivity in
all three subjects who underwent gene therapy in this study. The
increase in rod sensitivity was localized to the retinal regions
exposed to the therapy. The magnitude of the increase differed
Fig. 4. Pathophysiology of complex visual loss resulting from photoreceptor
degeneration and biochemical blockade, and the effect of gene therapy. (A)
Retinal cross-sectional images at the region of maximal biological activity show
the photoreceptor layer (ONL, brackets) to be abnormally thinned; greater
degeneration of photoreceptors is evident in patient 1 compared with patient 2.
Normal retina and patient 2 are at5 mm superior retina, patient 1 is at5 mm
inferior retina.SchematicsofphotoreceptorsandRPEareoverlaid (yellow)andto
the right of the actual optical images; these are derived from cynomolgus
monkeyhistology (3,28). INL, innernuclear layer;PR-ISandPR-OS,photoreceptor
inner and outer segments. (B) The relationship between photoreceptor layer
thickness and rod sensitivity loss in patients 1 and 2 before and after therapy
compared with normal subjects and patients with retinitis pigmentosa without
mutations in the RPE65 gene. Normal variability is described by the ellipse
encirclingthe95%C.I.ofabivariateGaussiandistribution.Dottedlinesdefinethe
idealized model of the relationship between structure and function in pure
photoreceptor degenerations and the region of uncertainty that results from
translating the normal variability along the idealized model. Gene therapy (ar-
rows) results in partial (patient 1) or a nearly complete (patient 2) amelioration of
the biochemical blockade transforming the complex RPE65-LCA disease pheno-
type into a simpler retinal degeneration phenotype.








among subjects, and those with a better preserved photoreceptor
layer in the treated region showed the greater increases in rod
vision. These psychophysical results, complimented by objective
evidence from dark-adapted pupillary reflexes, were consistent
with our previous demonstration that visual pathways from retina
to visual brain were intact and amenable to therapy despite the
congenital defect ofRPE65-LCA (22). The increased rod sensitivity
is likely driven by an increased synthesis of 11-cis-retinal chro-
mophore resulting from WT RPE65 protein introduced into the
RPE by expression from the AAV2 gene therapy vector. These
results in man add to the literature consensus that RPE65 is
essential in the regeneration of rod visual pigment (i.e., rhodopsin)
in vertebrates (1, 19, 31, 32). Both the magnitude of the increase
observed (up to 4.8 log10 units) in the human subjects and the lack
of visual function increase found with sham subretinal injections in
murine (Fig. S1) and canine (11) models with Rpe65 deficiency
essentially rule out alternative hypotheses for visual gain involving
the release of neurotrophic factors (33) secondary to subretinal
surgery (34).
Extremely prolonged recovery of rod vision after light exposure,
demonstrated by dark adaptation testing posttreatment in patients
2 and 3 (Fig. 3B), suggests a slowed delivery of 11-cis-retinal
chromophore from the RPE to the rod photoreceptors and thus a
protracted regeneration of light responsive rhodopsin. Two general
hypotheses to entertain for a slowing of the chromophore delivery
rate are (i) reduced rate of its synthesis or (ii) increased obstruction
to its inter- or intracellular transport. Abnormally low expression of
RPE65 (or other key retinoid cycle enzymes, ref. 35) could have
reduced the rate of chromophore synthesis and resulted in an
enzymatic limit to rhodopsin regeneration such as observed inmice
that express very low levels of WT Rpe65 (36, 37) or a mutant
Rpe65 protein (38). In previous studies, slowness of recovery of rod
vision in human diseases of the RPE (23–27) has been ascribed to
enzymatic limitation to the synthesis of chromophore (18). A
limited expression of RPE65 through gene therapy could have
caused such an enzymatic bottleneck. Unlike in disease states,
however, the normal human rhodopsin regeneration rate is believed
not to be enzymatically limited (18). Consistent with this hypothesis
is the demonstration of normal rate of dark adaptation in heterozy-
gotes for null mutations in RPE65 (39) andRDH5 (25) predicted to
express half the normal amount for the two key retinoid cycle
enzymes, the isomerase and the 11-cis-retinol dehydrogenase, re-
spectively. As an alternative to an enzymatic limit, the major
component of dark adaptation in normal human vision is hypoth-
esized to be rate-limited by a ‘‘resistive barrier’’ to 11-cis-retinal
diffusion or transport between RPE cells and rod photoreceptors
(18). The identity of the resistive barrier is currently unknown, and
it is possible that RPE65 disease exacerbates or adds to a natural
barrier. The dramatic accumulation of all-trans-retinyl esters and
lipid droplets observed in the RPE with RPE65 deficiency and/or
disorganized rod outer segments may contribute to such a barrier
(4, 9, 40, 41). Alternatively, the surgical detachment could have
altered the RPE/photoreceptor interface (42). Follow-up studies in
the current patients and other patients with similar or higher doses
of vector-RPE65 should help clarify the underlying cause of slowed
rod kinetics by considering dose and disease stage dependence of
the recovery rate as well as possible changes in dark adaptation rate
with time after treatment.
Arguably, cone photoreceptor-based daylight vision is usedmore
than night vision by people living in modern well-lit environments.
The role(s) played by RPE65 in providing chromophore for cone
function and/or survival remains unclear and controversial (1, 3, 40,
43–49). Restoration of cone- as well as rod photoreceptor-based
visual function by subretinalAAVgene therapy in the caninemodel
of RPE65-LCA (4, 8), together with the existence of remnant cone
function in patients with untreated RPE65-LCA (3), suggested a
potential to improve cone function in patients undergoing gene
therapy. Indeed, in two of the patients in the current study (patients
2 and 3), robust improvement in cone-mediated visual function
could be demonstrated (Fig. 3C). In the patient with the best
treatment response (patient 2), both cones and rods reached a level
of sensitivity within 1.5 log units of mean normal. Fast recovery
rate of cone dark adaptation function could be attributed to the
long-standing hypothesis of rod/cone competition, with cones ex-
tracting more of an extremely limited supply of 11-cis-retinal
chromophore (50). However, alternative hypotheses involving a
partial reconstitution of a cone-specific retinoid cycle by gene
therapy cannot be ruled out.
How do the present results compare with other similarly con-
ducted RPE65-LCA gene therapy trials? Maguire et al. (16) re-
ported increased visual acuity after treatment, but these increases
were from severely low levels of spatial vision to levels that were still
low; extrafoveal rods or cones could have subserved the posttreat-
ment levels of visual acuity reported. Improvement of vision in dim
light was self-reported by all three subjects (16) but the photore-
ceptor cell type subserving this vision was not characterized.
Bainbridge et al. (15) used dark-adapted thresholds and found as
much as 2 log units of increased vision in one patient, but again the
photoreceptor type mediating the improvement remained unclear
(15). The need to experimentally dissect rod- from cone-mediated
responses in our patients suggests that the source of visual improve-
ment with therapy cannot be presumed but must be measured. Of
note, none of our patients showed adecrease in nystagmus (Fig. S3),
contrary to an observation made in another trial (16). Contributing
to this discrepancy could be the large baseline differences in visual
acuity between the treatment cohorts; we have previously shown
fixation instability to be related to visual acuity in RPE65-LCA (3),
and treatment of patients with severe loss of central vision as in
Maguire et al. (16) could conceivably have different consequences
on eye movement abnormalities.
There are some key practical implications of the finding of slow
rod kinetics after treatment. Clinical trial protocols may need
reconsideration as this therapy advances beyond early stages. It is
evident that themaximum increase of vision after treatment cannot
be measured unless patients undergo dark adaptation for extended
periods of time. Comparisons of visual function improvement
between patients within a trial or between trials cannot be made
without rigorous attention to previous light exposure and length of
dark adaptation. The order of testing protocols will need careful
reconsideration. In particular, light exposures, such as fundus
photography, preceding measures of dark-adapted sensitivities
should be minimized. If monitoring the kinetics of adaptation
becomes an assay for treatment efficacy, an efficientmethod should
be devised, considering the lengthy time course we observed in two
patients.
Materials and Methods
Human Studies. Vision research studies were performed in eight patients with
LCA caused by mutations in the RPE65 gene and conducted according to
guidelines of the Declaration of Helsinki after obtaining written consent. All
studies were approved by the University of Pennsylvania Institutional Review
Board (nos. 186900, 701705, 700942, and 804582). Three of the patients were
assessed with these vision research studies before and after taking part in a
phase I clinical trial (trial NCT00481546, www.clinicaltrials.gov) evaluating the
safety of rAAV2-CBSB-hRPE65 (IND Number, BB-IND 12824). Safety results of
this clinical trial are published separately (17).
Photoreceptor Layer Topography. In vivo microscopy of the human retina was
performed with optical coherence tomography (OCT) as published (2, 3, 51).
A Fourier-domain OCT system (RTVue-100; Optovue) was used for data acqui-
sition, and postacquisition processing of data was performed with custom
programs (MatLab 6.5; MathWorks). Further details are described in the SI
Text.
Psychophysical Studies.Visual field testing was performed with kinetic and static
perimetry as published (3, 23–27, 52). For kinetic perimetry, white (318 cdm2)
targets of Goldmann sizes III (patient 1) or V (patients 2 and 3) were used on a 10
15116  www.pnas.orgcgidoi10.1073pnas.0807027105 Cideciyan et al.
cdm2 achromatic background. Fixation location and stability were quantified
(as described in SI Text) in all subjects studied. All subjects fixated at the anatom-
ical fovea; variability of the excursions from the fovea resulting from abnormal
eyemovementswasmuchsmallerthanthe0.6-mmsamplingdensityusedinstatic
perimetry (Fig. S3). In all three patients, there were no consistent changes in
fixation location or fixation instability before and after treatment (Fig. S3). Static
perimetric sensitivities were determined with a modified computerized perime-
ter (Humphrey Field Analyzer; Zeiss) under dark-adapted conditions (see SI Text
for details).
Modeling of the Relationship Between Retinal Structure and Visual Function.
The relationship between photoreceptor structure and co-localized visual func-
tion was defined in patients using ONL thickness and rod-mediated sensitivity.
Patient results were compared with an idealized model of the expected relation-
ship for ‘‘simple’’ photoreceptor degenerations in which vision loss is thought to
be derived primarily from degenerative photoreceptor cell loss. The model as-
sumesthatabsolutesensitivityofrod-mediatedfunctionnearthevisibilitythresh-
old is limited by quantum catch and is thus proportional to the product of the
number of surviving photoreceptor cells and the length of their outer segments;
both of these parameters are proportional to ONL thickness (2, 53, 54). Thus, to
a first approximation, loss of light sensitivity (in linear units) would be expected
to be proportional to the square of ONL thinning.
Animal Studies. Rpe65-deficient rd12 mice were injected subretinally with 4
108 vector genomes of rAAV2-CBSB-hRPE65, which remained after each hu-
man surgery. Electroretinograms obtained in vector-injected and control eyes
were used to determine the biological activity of the vector (13). Further
details are described in the SI Text.
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